Capricor Therapeutics' Duchenne treatment heading for FDA rejection
Source Summary
Capricor Therapeutics is attempting to prevent FDA rejection of its cell therapy for Duchenne muscular dystrophy.
Capricor Therapeutics is attempting to prevent FDA rejection of its cell therapy for Duchenne muscular dystrophy.
